895P - The Role of Metabolic Tumor Volume and Total Lesion Glycolysis on 18F-Fdg Pet/Ct in the Prognosis of Epithelial Ovarian Cancer

Abstract

ABSTRACT Aim: This study assessed the prognostic value of pre-operative 2-[18F] fluoro-2-deoxy-d-glucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) volumetric parameters, including metabolic tumor volume (MTV) and total lesion glycolysis (TLG), in patients with epithelial ovarian cancer. Methods: A total of 166 patients with epithelial ovarian cancer who underwent 18F-FDG PET/CT and subsequent cytoreductive surgery were retrospectively enrolled. Maximum standardized uptake value (SUVmax), MTV, and TLG on 18F-FDG PET/CT were measured for all patients. Univariate and multivariate analyses were performed to evaluate the prognostic significance of SUVmax, MTV, TLG, and clinicopathological factors for disease progression-free survival. Results: Disease progressed in 78 (47%) of the 166 patients, and the 2-year disease progression-free survival rate was 55.0%. Univariate analysis showed that tumor stage, histopathological type, presence of regional lymph node metastasis, residual tumor after cytoreductive surgery, pre-operative serum carbohydrate antigen 125 (CA125) level, SUVmax, MTV, and TLG were significant prognostic factors (p 100.0). Conclusions: Along with tumor stage, TLG is an independent prognostic factor for disease progression after cytoreductive surgery in patients with epithelial ovarian cancer. By combining tumor stage and TLG, one can further stratify the risk of disease progression for patients undergoing cytoreductive surgery. Disclosure: All authors have declared no conflicts of interest.